MT-2 Spray 10mg – Intranasal Melanotan II for Rapid CNS & Cutaneous Research

Intro Paragraph (250 words)
Our pharmaceutical-grade MT-2 Spray delivers Melanotan II (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂) in an advanced intranasal formulation optimized for rapid transmucosal absorption and enhanced central nervous system penetration. This non-invasive delivery system bypasses the hepatic first-pass metabolism and blood-brain barrier constraints associated with subcutaneous administration, providing researchers with a unique tool for investigating hypothalamic melanocortin signaling, rapid-onset appetite modulation, and sexual behavior endpoints without injection trauma variables. Each metered-dose spray bottle contains 10mg of high-purity cyclic heptapeptide, stabilized for mucosal delivery and calibrated for precise micro-dosing essential for CNS receptor saturation studies.

The intranasal route exploits the direct anatomical connection between the nasal cavity and central nervous system via the olfactory and trigeminal nerve pathways, allowing Melanotan II to reach the hypothalamus, amygdala, and hippocampus within minutes of administration. This pharmacokinetic profile proves invaluable for research requiring temporal precision—such as pairing melanocortin activation with specific behavioral paradigms, electrophysiological recordings, or functional imaging. Unlike the extended absorption kinetics of subcutaneous [Melanotan 2](#] injections, which require 30-60 minutes for peak plasma concentration, the MT-2 Spray format achieves rapid CNS receptor occupancy, enabling investigation into acute appetite suppression, immediate sexual arousal mechanisms, and rapid sympathetic activation without the confounding variables of injection stress or variable subcutaneous absorption rates.

For laboratories studying the central versus peripheral effects of melanocortins, this delivery format offers methodological advantages for isolating hypothalamic MC3R/MC4R activation from cutaneous MC1R effects, while still providing sufficient systemic absorption for investigating metabolic and tanning endpoints. When stored appropriately, this aqueous formulation maintains peptide stability for the duration of multi-week research protocols.

 Nasal Mucosa Absorption & Nose-to-Brain Transport Mechanisms

The MT-2 Spray format leverages the unique vascular anatomy of the nasal cavity, where the olfactory epithelium and respiratory mucosa provide direct access to the CNS through extracellular bulk flow along olfactory nerve axons and intracellular transport within trigeminal nerve sensory neurons. This “nose-to-brain” pathway allows Melanotan II to circumvent the restrictive blood-brain barrier, achieving cerebrospinal fluid concentrations disproportionate to plasma levels—a pharmacokinetic profile impossible to replicate with parenteral administration alone.

Olfactory Bulb Targeting:
Research utilizing intranasal MT-2 demonstrates rapid accumulation within the olfactory bulb and subsequent distribution to limbic structures including the hypothalamus and amygdala. This targeting proves particularly relevant for research into the melanocortin modulation of sexual behavior, where the medial amygdala and bed nucleus of the stria terminalis represent critical integration sites for olfactory and hormonal cues. The spray format allows researchers to investigate pheromone-melanocortin interactions with temporal precision impossible using slower-absorbing injection protocols.

Reduced Systemic Exposure:
While sufficient Melanotan II reaches systemic circulation via nasal mucosal vasculature to stimulate cutaneous melanogenesis, the CNS-preferential distribution achieved through intranasal delivery reduces the total dose required for central effects. This differential biodistribution potentially minimizes peripheral side effects—including nausea mediated by area postrema activation—while maintaining hypothalamic MC4R engagement for appetite and metabolic research. Studies comparing intranasal versus subcutaneous MT-2 can investigate dose-response relationships for central versus peripheral melanocortin effects.

Mucosal Permeation Enhancement:
The compact cyclic structure of Melanotan II (1,024 Da) facilitates passive diffusion across nasal epithelial tight junctions, while its lipophilic character (conferred by the Nle⁴ and Trp⁹ residues) enables transcellular absorption through lipid bilayers. Unlike larger peptides requiring chemical penetration enhancers, MT-2 demonstrates satisfactory bioavailability through physiological nasal mucosa, though research protocols should account for individual variations in mucociliary clearance and nasal congestion that may affect absorption consistency.

 Research Applications & Methodological Advantages

Central Sexual Dysfunction Research:
The primary research application for MT-2 Spray involves investigating psychogenic sexual arousal through rapid hypothalamic MC4R activation. Unlike phosphodiesterase inhibitors that require peripheral vascular integrity, intranasal Melanotan II directly stimulates central arousal pathways, allowing researchers to distinguish vascular erectile dysfunction from hypothalamic-pituitary-gonadal axis dysfunction. The spray format enables precise timing of administration relative to behavioral testing, with onset of action typically 10-20 minutes post-instillation versus 60-90 minutes for subcutaneous delivery.

Appetite & Satiety Studies:
Research into melanocortin-induced anorexia benefits from the rapid CNS penetration of intranasal delivery. The MT-2 Spray allows investigation into the immediate satiety signals generated by paraventricular nucleus (PVN) MC4R activation, including the temporal relationship between peptide administration, sympathetic nervous system activation, and feeding cessation. Studies can examine whether rapid CNS saturation produces qualitative differences in satiety perception compared to gradually increasing plasma concentrations from injectable formats.

Metabolic Rate & Thermogenesis:
The sympathetic activation induced by hypothalamic MC4R stimulation—increasing brown adipose tissue thermogenesis and lipolysis—can be precisely timed using the MT-2 Spray format. Researchers investigating the acute metabolic effects of melanocortins, including indirect calorimetry measurements and core temperature monitoring, benefit from the predictable onset kinetics of nasal delivery, avoiding the absorption variability inherent in subcutaneous adipose tissue deposition.

Comparative Tanning Research:
While subcutaneous [Melanotan 2](#] remains the standard for cutaneous melanogenesis research, the MT-2 Spray format allows investigation into whether CNS-preferential dosing affects the psychological or endocrine components of UV-seeking behavior, or whether intranasal delivery produces differential melanin distribution patterns compared to systemic circulation. The spray format also proves useful for research into localized nasal mucosa pigmentation or melanocortin effects on olfactory sensitivity.

 Product Specifications & Formulation Details

• Active Compound: Melanotan II (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂)
• Delivery System: Metered-dose nasal spray pump
• Total Content: 10mg Melanotan II per bottle
• Concentration: ~0.5-1mg/ml (varies by specific formulation/dilution)
• Dosing per Actuation: Approximately 100mcg per spray (100 actuations total)
• Formulation: Aqueous solution with preservative and isotonic agents
• pH: 6.0-7.0 (physiological for mucosal tolerance)
• Purity: ≥98% (HPLC verified prior to formulation)
• Stability: 30 days refrigerated at 2-8°C after opening
• Storage: 2-8°C (refrigerated), protect from light and freezing

Quality Control:
Each batch tested for sterility, endotoxin levels (<0.5 EU/ml), and osmolarity (280-320 mOsm/kg) to ensure mucosal compatibility. Peptide content verified via HPLC after formulation to confirm stability in aqueous spray medium. The cyclic structure integrity confirmed through circular dichroism spectroscopy to ensure retention of the bioactive lactam conformation necessary for MC4R binding.

Administration Protocols & Research Methodologies

Intranasal Technique Standardization:
For reproducible research outcomes, standardize administration technique: subjects should clear nasal passages, tilt head slightly forward (not back, to prevent throat runoff), and actuate the MT-2 Spray while inhaling gently through the nose. Hold breath for 5-10 seconds post-instillation to maximize mucosal contact time and minimize nasopharyngeal drip that would result in oral ingestion (gastric degradation).

Dosing Calculations:
With approximately 100mcg per actuation, researchers can achieve precise dose titration impossible with injectable formats requiring volume measurement. Typical research doses range from 100-300mcg (1-3 sprays) for CNS effects, and 500-1000mcg (5-10 sprays) for combined central and peripheral effects comparable to 0.5-1mg subcutaneous [Melanotan 2](#]. Dose-response curves should account for the ~30-50% bioavailability of intranasal versus subcutaneous routes.

Timing Considerations:
Onset of central effects (appetite suppression, subjective arousal) typically occurs within 10-20 minutes, peak effects at 30-60 minutes, and duration of 2-4 hours. This rapid pharmacokinetic profile contrasts with the 6-8 hour duration of subcutaneous injections, allowing for multiple daily dosing paradigms or precise timing relative to behavioral assays.

Comparison to DSIP Spray:
Unlike [DSIP Spray](#], which targets sleep architecture through GABA-ergic modulation and requires evening administration, MT-2 Spray produces alerting, sympathomimetic effects suitable for daytime research protocols. The two nasal sprays represent opposite ends of the behavioral pharmacology spectrum—sedation versus arousal—allowing researchers to investigate circadian-appropriate peptide delivery through the same non-invasive route.

 Comparative Analysis: MT-2 Spray vs. Injectable Formats

Pharmacokinetic Distinctions:
Subcutaneous [Melanotan 2](#] provides sustained plasma levels over 6-8 hours with gradual CNS penetration, suitable for research requiring prolonged receptor activation. The MT-2 Spray format produces rapid peaks and shorter duration (2-4 hours), ideal for acute behavioral studies or protocols requiring multiple discrete activation periods. Research comparing these routes can investigate whether pulsatile versus sustained melanocortin signaling produces different adaptive responses in receptor desensitization or metabolic adaptation.

Subject Compliance & Stress Variables:
Injection protocols introduce stress hormones (cortisol, epinephrine) that may confound metabolic and behavioral research. The MT-2 Spray eliminates injection trauma, needle phobia variables, and associated sympathetic activation, providing cleaner data for studies investigating pure melanocortin pharmacology without procedural confounders. This proves particularly valuable in chronic administration studies where injection site reactions or lipohypertrophy might limit research duration.

Bioavailability Considerations:
While subcutaneous delivery achieves ~100% bioavailability (minus local enzymatic degradation), intranasal MT-2 delivers approximately 30-50% of the dose to systemic circulation, with significant CNS targeting via the olfactory route. Research must account for this differential when translating dosing from injectable literature, typically requiring 2-3x higher nominal doses to achieve equivalent peripheral effects, while potentially achieving superior central effects at lower equivalent doses.

 Storage, Stability & Handling Considerations

Aqueous Formulation Stability:
Unlike lyophilized powders requiring [bacteriostatic water](#] reconstitution, the MT-2 Spray arrives as a ready-to-use aqueous formulation. However, this convenience requires strict adherence to storage protocols: the aqueous environment accelerates oxidation of the tryptophan residue and potential hydrolysis of the cyclic lactam bond compared to lyophilized preparations.

Critical Storage Parameters:

• Maintain continuous refrigeration at 2-8°C; never freeze (ice crystals disrupt the peptide and damage pump mechanism)
• Protect from light (amber bottle or aluminum wrapping) to prevent photodegradation
• Use within 30 days of first activation to prevent microbial contamination and oxidative degradation
• Store upright to prevent leakage and ensure consistent dosing per actuation

Cross-Contamination Prevention:
As with all peptide nasal sprays, designate specific pumps for individual research subjects to prevent transmission of nasal flora or viral particles. The preservative system (typically benzalkonium chloride or similar) provides antimicrobial protection but does not eliminate the risk of cross-contamination in multi-subject research protocols.

 Frequently Asked Research Questions

How does intranasal MT-2 bioavailability compare to injections?
Intranasal MT-2 achieves approximately 30-50% systemic bioavailability compared to subcutaneous injection, but offers superior CNS penetration via the olfactory pathway. For central effect research (appetite, sexual behavior), lower doses may produce equivalent hypothalamic concentrations compared to injectable routes.

Can MT-2 Spray be used for tanning research?
Yes, though higher nominal doses are required to achieve systemic levels comparable to injections. The spray format primarily advantages CNS/pituitary research; for pure cutaneous melanogenesis studies, subcutaneous [Melanotan 2](#] remains more dose-efficient and cost-effective.

What is the onset time for behavioral effects?
Central effects (appetite suppression, subjective arousal) typically manifest within 10-20 minutes of intranasal administration, significantly faster than the 45-90 minutes required for subcutaneous absorption and blood-brain barrier penetration.

Does the spray format reduce nausea side effects?
Research suggests intranasal delivery may produce less severe nausea than subcutaneous administration, potentially due to reduced area postrema activation from lower peak plasma concentrations, though individual variability exists. The rapid CNS saturation may also allow lower total doses for equivalent central effects.

How should this be stored compared to lyophilized peptides?
Unlike [BPC-157](#] or [GHK-Cu](#] powders that tolerate -20°C frozen storage for years, the MT-2 Spray requires continuous 2-8°C refrigeration and has a limited 30-day shelf life after opening due to the aqueous formulation. Do not freeze, as this damages the pump mechanism and causes peptide aggregation.